Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

Saved in:
Bibliographic Details
Title: Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial.
Authors: Cook G; Department of Haematology, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. Electronic address: g.cook@leeds.ac.uk., Ashcroft AJ; Mid-Yorkshire NHS Trust, Wakefield, UK., Senior E; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Olivier C; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Hockaday A; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Richards J; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Cavenagh JD; Department of Haematology, Barts Health NHS Trust, London, UK., Snowden JA; Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK; Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK., Drayson MT; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK., de Tute R; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK., Roberts L; Leek, UK., Owen RG; Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK., Yong K; University College London Hospitals, NHS Foundation Trust, London, UK., Garg M; Leicester Royal Infirmary, Leicester, UK., Boyd K; Department of Haematology, Royal Marsden Hospital, London, UK., Sati H; Department of Haematology, Singleton Hospital, Swansea, UK., Gillson S; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Cook M; Bristol-Myers Squibb, Boudry, Switzerland., Cairns DA; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK., Parrish C; Department of Haematology, Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK; Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
Corporate Authors: United Kingdom Myeloma Research Alliance
Source: The Lancet. Haematology [Lancet Haematol] 2024 Nov; Vol. 11 (11), pp. e816-e829. Date of Electronic Publication: 2024 Sep 06.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2352-3026
DOI:10.1016/S2352-3026(24)00249-7